Table 4.
Results of univariate analysis of the factors that influence the OS.
| Characteristics | n=33 (%) | Median OS (months) | p value |
|---|---|---|---|
| Sex | |||
| Male | 23 (69.7) | 37 | 0.721 |
| Female | 10 (30.3) | 22 | |
|
| |||
| Age | |||
| <60 | 15 (45.5) | 31 | 0.915 |
| ≥60 | 18 (54.5) | 33 | |
|
| |||
| Type | |||
| IgG | 21 (63.6) | NR | 0.243 |
| IgA | 1 (3.0) | 33 | |
| Light chain | 8 (24.2) | 7 | |
| Others | 3 (9.1) | 38 | |
|
| |||
| Bone marrow | |||
| Deauville score ≥4 | 10 (30.3) | 7 | 0.013 |
| Deauville score <4 | 23 (69.7) | 38 | |
|
| |||
| Paramedullary disease | |||
| + | 17 (51.5) | 33 | 0.513 |
| − | 16 (48.5) | 37 | |
|
| |||
| Extramedullary disease | |||
| + | 16 (48.5) | 16 | 0.015 |
| − | 17 (51.5) | NR | |
| Creatinine | |||
| <2 mg/dl | 22 (66.7) | 37 | 0.064 |
| ≥2 mg/dl | 11 (33.3) | 16 | |
|
| |||
| Subgroup of DS Plus | |||
| A | 12 (36.4) | NR | 0.012 |
| B | 21 (63.6) | 16 | |
|
| |||
| Treatment | |||
| None | 11 (33.3) | 31 | 0.146 |
| Chemotherapy | 7 (21.2) | 37 | |
| Chemotherapy + IMIDs | 9 (27.3) | NR | |
| Chemotherapy + BMT | 4 (12.1) | 27 | |
| Others | 2 (6.1) | 7 | |
NR: not reached; BMT: bone marrow transplant.